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ABSTRACT (246, max 250 words) 
OBJECTIVES: Whilst several antiretroviral drugs (ARVs), including the d-drugs stavudine 
(d4T) and didanosine (ddI), may cause biomarker-defined hepatotoxicity, their 
association with clinically defined end-stage liver disease (ESLD) and hepatocellular 
carcinoma (HCC) remains unknown.  
DESIGN: Prospective cohort study 
METHODS: D:A:D participants were followed until the first of ESLD (variceal bleeding, 
hepatic encephalopathy, hepatorenal syndrome or liver transplantation), HCC 
(histology or alpha-fetoprotein plus imaging), death, 6 months after last visit or 
1/2/2014. Associations between ESLD/HCC and cumulative use of individual ARVs were 
investigated using Poisson regression adjusting for potential confounders.                                                                                                               
RESULTS: During a median follow-up of 8.4 years, 319 ESLD/HCC cases occurred 
(incidence 1.01/1000 person-years [95%CI 0.90-1.12]) with a 62.6% one-year mortality 
rate. After adjustment, cumulative (per 5 years) exposure to d4T (relative rate 1.46 
[95%CI 1.20-1.77]), ddI (1.32 [1.07-1.63]), tenofovir (TDF, 1.46 [1.11-1.93]) and 
(fos)amprenavir (APV, 1.47 [1.01-2.15]) was associated with increased ESLD/HCC rates. 
Longer exposure to emtricitabine (0.51 [0.32-0.83]) and nevirapine (0.76 [0.58-0.98]) 
were associated with lower ESLD/HCC rates. The ddI/d4T-associated increased 
ESLD/HCC rate only started to decline 6 years after cessation.  
CONCLUSION: Cumulative use of d4T, ddI, TDF and APV were independently 
associated with increased ESLD/HCC rates, and intensified monitoring of liver function 
should hence be considered amongst all individuals exposed for longer time-periods. 
The use of d-drugs should furthermore be avoided, where there are alternatives 
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available and focus should be put on those with longer-term d-drugs exposure who 
remain at increased ESLD/HCC risk. The unexpected, and viral hepatitis independent, 
TDF association calls for further investigations.  
 
KEY WORDS; end-stage liver disease, hepatocellular carcinoma, hepatotoxicity, HIV, d-
drugs, (fos)amprenavir, tenofovir 
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TEXT (3.495 words, max 3500)                                                                                                                                               
Introduction 
The majority of the antiretroviral (ARV) drug classes used for the treatment of HIV 
have an intrinsic potential to cause hepatotoxicity, which may be induced through 
various mechanisms [1-4]. Previous studies have estimated that up to 30% of all HIV-
positive persons will experience some form of hepatotoxicity associated with ARV 
treatment (ART) [1-3]. Studies that have investigated adverse ART-liver effects have 
commonly been based on changes in liver-related biomarkers such as transaminases 
[3, 5-9], fibrosis markers (e.g. hyaluronic acid ) [10], imaging modalities or biopsy 
findings [11-17]. Furthermore, most studies have been of a relatively modest size or of 
a cross-sectional nature, making assessments of the time course between exposure 
and outcomes difficult [13-19].  Studies have also been conducted primarily among 
individuals who are co-infected with HIV and viral hepatitis, in whom the incidence of 
adverse hepatic impairment is elevated  compared to HIV mono-infected individuals 
[5, 14, 18, 20, 21]. Indeed, a previous D:A:D analysis in participant without viral 
hepatitis  found that deaths related to liver failure are rare in HIV-positive individuals 
without viral hepatitis B (HBV) or C (HCV) [20]. 
The adverse effects of ART on development of liver impairment have been debated for 
years [20, 22-25]. The diverse study outcomes are, however, not surprising as these 
will naturally depend on the individual ARV investigated. ART is known to have an 
overall beneficial effect on liver-related outcomes, largely due to attenuating liver 
disease progression in viral hepatitis co-infected individuals by  improvements in 
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immune function [22, 24], and the direct antiviral effect on HBV by certain individual 
ARVs such as tenofovir (TDF), lamivudine (3TC) and emtricitabine (FTC). Conversely, 
other ARVs, such as tipranavir (TPV), have a known direct hepatotoxic effect [4]. 
Furthermore, an excess risk of liver-related death with cumulative ART use has been 
observed after accounting for improvements in the CD4 cell count [24, 26]. 
Among the individual ARVs, dideoxynucleoside analogues or ‘d-drugs’ and, in 
particular, didanosine (ddI) and stavudine (d4T), have commonly been associated with 
alterations in liver function and severe steatosis/fibrosis development [11, 13, 16, 17, 
27-31]. Moreover, ddI use has been linked with development of non-cirrhotic portal 
hypertension [32, 33]. Use of d-drugs is now rare in most high-income countries due to 
their serious adverse effects including neuropathy and lipodystrophy [4]. D-drug use 
was, however, common in the past, and previous exposure may also impact on 
subsequent liver function [34]. In 2010 the WHO launched an initiative aiming to 
reduce the use of d4T. However, many individuals in resource-limited settings continue 
to use d-drugs due to their widespread availability and low cost; as such, an estimated 
1.1 million individuals still initiated a d4T-based first-line ARV regimen in 2011 [35, 36].  
 Of the non-nucleoside reverse transcriptase inhibitors (NNRTIs), in particular 
nevirapine (NVP) has been linked to hepatotoxicity as part of a systemic 
hypersensitivity reaction [1, 26, 37-39]. Compared to the suspected liver 
steatosis/fibrosis effect of d-drugs and other nucleoside reverse transcriptase 
inhibitors (NRTIs), the NNRTI class effect on the liver is of a hepatitis-like nature [1, 4, 
26, 37-39].  
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Among the protease inhibitors (PIs), particular atazanavir (ATV) may cause 
hyperbilirubinemia and cholecystolithiasis, whilst TPV-related hepatitis is expected in 
10% of recipients [4, 40, 41]. Co-infection with viral hepatitis has been associated with 
increased plasma levels of PIs, but the clinical impact of co-infection on ARV-related 
hepatotoxicity is unknown [42]. 
Whilst most ARV-related adverse liver effects are reported to be acute, mild and 
asymptomatic [3], prospective investigations of long-term ARV use and clinical 
manifestations of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) 
have not, as yet, been conducted in a large heterogeneous cohort setting. This analysis 
aimed to describe incidence rates (IRs), predictors and survival after ESLD/HCC with 
focus on the potential association with cumulative use of individual ARVs, and in 
particular d-drugs, due to their high susceptibility to induce fibrosis.  
Methods 
Study population 
The Data Collection on Adverse events of Anti-HIV Drugs Study (D:A:D) is a prospective 
cohort collaboration established in 1999 which follows more than 49,000 HIV-1-
positive persons in Europe, the United States and Australia; details have been 
published previously [17]. Data on clinical events including ESLD, cancers, myocardial 
infarction, stroke, invasive cardiovascular procedures and death are collected in real-
time during routine clinical care.  Events are validated centrally and monitored 
regularly.  In addition, information on demographic factors, ART, viral hepatitis, 
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laboratory test results, cardiovascular risk factors and AIDS events is collected 
electronically at enrolment and every six months.  
Endpoint definition 
From 1/2/2004 onwards systematic collection of ESLD and cancer events (including 
HCC) was initiated in D:A:D. A designated ESLD event form was developed to collect 
detailed information on the clinical symptoms defining ESLD: bleeding from 
endoscopically verified gastric or oesophageal varices; stage III-IV hepatic 
encephalopathy; hepatorenal syndrome; or liver transplantation (more information at 
www.chip.dk). In addition, pathology reports and transient elastographies results are 
collected.  Information on HCC, including histology findings or the combination of 
elevated alpha-fetoprotein and HCC specific imaging findings, is collected on a 
designated cancer form.  Where a diagnosis of ESLD/HCC was reported only on a fatal 
case reporting form (Coding Causes of deaths in HIV, CoDe, more information at 
www.chip.dk) [43], the death was only considered to be an ESLD or HCC event if 
information was provided on the clinical symptoms and histology/imaging findings.  
Statistical methods 
D:A:D participants were followed from the date of enrolment in the study or 1/2/2004, 
if this was later (baseline), until the first of an ESLD/HCC event, death, six months after 
last visit or 1/2/2014. Only the first ESLD or HCC event reported for each individual 
during prospective follow-up was included in the analysis. IRs were calculated per 1000 
person years of follow-up (PYFU). Kaplan-Meier estimation was used to describe the 
risk of mortality following a diagnosis of ESLD/HCC. Poisson regression models were 
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used to quantify the relationship between ESLD/HCC and cumulative ARV use.  
Potential confounders considered for adjusted models were calendar year [categorised 
as before 2008, 2008/2009 and after 2009], demographic variables (gender, age [<35 
or >35 years], ethnicity [Caucasian vs. other], participating cohort, smoking status 
[current, previous, never, unknown]), HIV-related factors (route of HIV acquisition [IDU 
vs. other], previous AIDS diagnosis) and HBV and HCV co-infection status [negative, 
positive, unknown]), with variables retained in multivariable models if they were 
significantly associated (p<0.05) with the outcome in univariate models.   
Subsequent models also considered adjustment for the latest viral load [VL, fitted 
categorically] and CD4 count, both as time-updated covariates; these covariates were 
purposely not included in our primary analyses of ARV associations, as they may lie on 
the causal pathway between ARV exposure and ESLD/HCC. 
ARV exposure was fitted cumulatively (per 5 years) as it was hypothesised that the risk 
of any adverse liver events would increase with longer exposure [44]. All ARV 
exposures were considered, regardless of when they accrued– thus, individuals may 
already have accrued several years of exposure to some of the ARVs prior to baseline; 
exposure then continued to accrue after baseline if the individuals continued to 
receive the drugs (or restarted them at a later point in time).   
An investigation of the association between time since d-drug discontinuation and 
ESLD/HCC rates was conducted adjusting for cumulative exposure to each drug and 
other potential confounders. This allowed us to assess the potential for any increased 
risk of ESLD/HCC to be reversed after cessation of the drug. 
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All statistical analyses were carried out using SAS version 9.3 (Statistical Analysis 
Software, Cary, NC, USA). 
Results 
Characteristics  
 A total of 45,544 individuals were followed in D:A:D from 1/1/2004 and were included 
in the analysis; these individuals were predominantly Caucasian (49.6%), male (73.5%) 
and had acquired HIV through sex between men, MSM (44.5%) (Table 1). The median 
age was 40 (interquartile range [IQR] 34-46) years at baseline and the median CD4 
count 434 (IQR 282-621) cells/mm3. During a median FU of 8.4 (IQR 5.5-12.6) years a 
total of 319 ESLD/HCC events occurred (IR 1.01/1000 PYFU, 95% confidence interval 
[CI] 0.90-1.12) of which 209 were ESLD and 110 HCC events. Overall, 157 (49.2%) of the 
ESLD/HCC events were identified through an ESLD form, 88 (27.6%) through a cancer 
form, and the remaining 74 (23.2%) through a death form. The most common clinical 
manifestation of ESLD was hepatic encephalopathy grade III-IV (43.3%), followed by 
endoscopically verified variceal bleeding (27.4%), hepatorenal syndrome (14.6%) and 
liver transplantation (5.1%), while 9.6% had more than one manifestation at the same 
event date. The median age of individuals experiencing ESLD/HCC (at the time of the 
event) was 47 (IQR 42-52) years, the most common mode of HIV acquisition was 
injection drug use (IDU, 53.6%), the median CD4 cell count was 266 (IQR 153- 448) 
cells/mm3 and 72.4% were confirmed HCV positive and 39.9% HBV positive (Table 1). 
As 82.8% of all events occurred in individuals co-infected with viral hepatitis the 
ESLD/HCC IR was low in individuals without HCV or HBV evidence (0.19/1000 PYFU 
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[95% CI 0.13- 0.26])  (Table 2). Whilst the ESLD/HCC IR was similar for individuals with 
HIV/HCV and HIV/HBV co-infection the number of individuals with HIV/HCV/HBV was 
limited (data not shown).  
Prognosis 
The 319 individuals with ESLD/HCC were followed for a median of 0.23 (IQR 0.01-1.88) 
years after diagnosis, over which time 241 (75.6%) died. The median survival after an 
ESLD/HCC diagnosis was 0.27 years, while the one-year mortality rate (Kaplan-Meier 
estimate) was 62.6%. After exclusion of 52 individuals diagnosed with ESLD/HCC at 
time of death, the median survival after an ESLD/HCC event was 0.66 years and the 
one-year mortality rate 55.0%. 
Associations between ARV exposure and ESLD/HCC 
Associations between individual ARVs and ESLD/HCC were initially explored without 
adjustment for calendar year, demographics, HIV-related factors and viral hepatitis 
status (but with adjustment for other ARVs in the regimen) (Figure 1).   
Among the NRTIs, a linear and similar cumulative effect of ddI and d4T was observed 
(d4T 1.80/5 years [1.42-2.27] and ddI 1.55/5 years [1.25-1.92]).  Increased exposure to 
3TC (1.31/5 years [1.07-1.60]) and TDF (1.55/5 years [1.17-2.04]) were unexpectedly 
also associated with increased rates of ESLD/HCC. In contrast, a reduced rate of 
ESLD/HCC was seen in individuals with longer exposure to FTC (0.54/5 years [0.34-
0.86]).  After adjustment for potential confounders, significant associations remained 
with cumulative use of d4T (1.46/5 years [1.20-1.77]), ddI (1.32/5 years [1.07- 1.63]), 
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TDF (1.46/5 years [1.11-1.93]) and FTC (0.51/5 years [0.32-0.83]), while the association 
with 3TC no longer remained significant (Figure 1). 
Among the NNRTIs use of NVP was surprisingly associated with a reduced rate of 
ESLD/HCC in both unadjusted (0.56/5 years [0.43-0.74]) and adjusted (0.76/5 years 
[0.58-0.98]) analyses. 
(Fos)amprenavir (APV) was the only PI associated with ESLD/HCC in unadjusted models 
(1.82/5 years [1.16-2.85]) and this association remained significant in the fully adjusted 
multivariate model (1.47/5 years [1.01-2.15]).    
A sensitivity analysis stratified according to viral hepatitis status reached consistent 
associations for all ARVs, including TDF, although the number of events was low in 
those without evidence of HBV/HCV (data not shown). 
The associations with ddI and d4T were explored in more detail, as determined a priori 
due to the potential long terms effects on liver function after ceased use.  When 
exposure to ddI was considered without any d4T exposure, the association between 
ddI and ESLD/HCC was reduced slightly (1.28/5 years [0.98-1.66]) as was d4T exposure 
when used without ddI (1.43/5 years [1.16-1.77]).  When used concomitantly the 
association with ESLD/HCC was strengthened (2.03/5 years [1.44-2.85]), however, only 
to the extent that would be expected on the basis of combining the effects of each 
drug when used separately, as there was no evidence of synergy  between the two 
drugs in this model.  There was no strong evidence to indicate that the associations 
between the two d-drugs and ESLD/HCC differed between individuals with and without 
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viral hepatitis co-infection (p=0.50 for interaction between d4T and any hepatitis, 
p=0.09 for ddI and any hepatitis), although due to the small number of events in those 
without co-infection, the power to detect a significant interaction was extremely low. 
Of the 18,676 persons on d4T or ddI, 91.4% stopped their use at least once during 
follow-up, with only 18.4% of the PYFU in those exposed to d-drugs being current 
users. Those having previously stopped d-drugs had higher ESLD/HCC rates than those 
currently on d-drugs, an effect that only started to wane slightly after more than six 
years after cessation (Table 3). 
 
Discussion 
This is the first large, prospective and long-term analysis to investigate incidence, 
outcomes and risk factors for clinically defined liver failure and cancer in HIV-positive 
persons with focus on the contribution of individual ARVs.  
We observed a relatively low overall IR of ESLD/HCC in this large heterogeneous cohort 
of both HIV mono- and viral hepatitis co-infected persons. In comparison, a recent 
retrospective analysis from the VA cohort found that among ARV-treated HIV/HCV co-
infected persons, 7.4 % experienced hepatic decompensation at 10 years [45]. This 
higher rate may, however, be explained by the conservative ESLD/HCC criteria in 
D:A:D, and by the inclusion of ascites in the definition of hepatic decompensation, 
which was not originally included in the D:A:D definition as it may also be seen in other 
non-cirrhotic liver disease-related conditions [46]. 
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The prognosis following ESLD/HCC was poor with a median one-year survival of only 
0.27 years. This observation calls for an increased awareness of ESLD/HCC risk factors 
and management. The recent introduction of effective direct acting agents (DAAs) for 
treatment of HCV will likely change the ESLD/HCC incidence and survival over the years 
to follow.  
ARV risk factors of ESLD/HCC 
We identified cumulative use of ddI, d4T, TDF and APV to be independently associated 
with an increased rate of ESLD/HCC development, while use of FTC and NVP were 
associated with decreased rates.  
The association between cumulative ddI and d4T use and excess ESLD/HCCIR builds on 
the observations of a number of relatively small studies of HIV- mono and viral 
hepatitis co-infected individuals using various biomarkers of liver failure [5, 14, 18]. A 
recent retrospective study among 146 HIV/HCV co-infected persons found that each 
additional year of use of these drugs was associated with a 50% increase in the odds of 
progressing one or more grades on the Brunt score [15]. Likewise, a subanalysis among 
205 HIV/HCV co-infected persons randomised to two types of anti-HCV treatment 
found that ddI use was associated with three-fold higher odds of histologically verified 
fibrosis [16], and a European cross-sectional study of 671 HIV/HCV co-infected persons 
found that a median use of ddI exceeding 5 months increased the odds of severe liver 
fibrosis by 70%  [13].  
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The IR of ESLD/HCC among those who had been exposed to ddI and/or d4T was higher 
among individuals who had discontinued the drugs, than among those currently 
receiving them.  This may reflect the fact that those at highest underlying risk of 
ESLD/HCC may be most likely to stop the d-drugs. Several mechanisms have been 
suggested for d-drug hepatotoxicity including inhibition of the mitochondrial DNA 
polymerase gamma and the mitochondrial respiratory chain with resulting oxidative 
damages and lactic acidosis [3, 16, 47, 48], hepatic steatosis (micro- and 
macrovascular), hepatocellular damage and ultimately development of cirrhosis [13, 
15]. 
 The observed higher incidence of ESLD/HCC did not begin to decrease until six years 
after cessation of ddI and d4T, suggesting that exposure to the drugs may have caused 
irreversible tissue damage. This finding is in accordance with work from Scourfield et 
al. who found that the adverse liver effects of ddI developed late and after use of the 
drug was discontinued [34]. These observations hence have important implications for 
the clinical management of all HIV-positive persons with current or prior d-drug use. 
Use of d-drugs should therefore be avoided if possible, in particular in individuals with 
high underlying risk of ESLD/HCC such as those with viral hepatitis. Due to the long-
lasting adverse effects of d-drugs also after their use have been discontinued one 
might further consider intensifying monitoring with liver-biomarkers, and if abnormal, 
by transient elastography or liver biopsy among individuals with long-term prior d-drug 
use to better identify individuals at increased ESLD/HCC risk.  
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In contrast to the associations seen with ddI and d4T, the observed association 
between ESLD/HCC and TDF was unexpected. As TDF may be used preferentially 
among those with HBV co-infection, it may not be surprising that we see an increased 
rate of hepatotoxicity in those exposed to this drug [1, 49]. Importantly, however, the 
TDF association remained unchanged after stratifying according to and adjusting for 
viral hepatitis status, suggesting the association is not dependent on HBV and is not 
simply explained by an increased ESLD/HCC risk among individuals co-infected with 
HBV and preferentially treated with TDF. Furthermore a recent D:A:D analysis which 
investigated predictors of chronic liver enzyme elevation among individuals without 
viral hepatitis, also confirmed the positive association with cumulative TDF use, 
supporting this observation [50]. Finally 3TC, which is also used to treat HBV-infection, 
although less often due to a lower genetic resistance barrier, did not remain 
statistically significantly associated with ESLD/HCC in adjusted models. Use of FTC, 
which is commonly co-prescribed with TDF (68% of those currently on TDF were also 
on FTC) was further independently associated with a lower ESLD/HCC risk and further 
argues against the hypothesis that our observed TDF association simply reflects a 
higher rate of unreported HBV infection. Outside the D:A:D study, only a few studies, 
predominantly smaller case reports, have reported a positive association between liver 
impairment and TDF [49, 51, 52]. This TDF association does, however, seem to be 
robust in D:A:D and is related to several liver outcomes, calling for confirmation in 
other large studies. No biological mechanism is currently known for TDF to cause 
ESLD/HCC, but the effect may relate to the development of mitochondrial toxicity in 
hepatocytes as described in renal tubular cells [53], and steatosis is described in the 
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TDF product information [54]. Our results call for further investigations in mechanistic 
studies.  
Based on the literature, if anything, one would have expected use of NVP to be 
associated with increased risk of ESLD/HCC [1, 26, 37-39]. Instead, we observed a 
lower rate of ESLD/HCC associated with cumulative NVP use. This may reflect the fact 
that NVP may only contribute to acute, but not more advanced and chronic stages of 
liver disease, but may also reflect some degree of confounding by indication with NVP 
not being prescribed to high risk individuals, or being discontinued in those who 
experience liver enzyme elevations after starting the drug. 
Elevated levels of transaminases are a common adverse effect of APV, although a 
recent small study did not identify a safety concern with long term use [55, 56]. A 
recent mechanistic study further found some evidence to support an anti-HCC effect of 
APV [57]. APV may, due to its use in calculating dose recommendations for various 
levels of liver impairment, preferably have been used in individuals with liver 
impairment and use is currently limited[58]. No other statistically significant 
associations were observed for cumulative use of other PIs including ATV. This 
suggests that from a clinical liver endpoint perspective the commonly used PIs can be 
safely used in HIV-positive individuals over longer periods of time, a finding that is in 
accordance with other recent studies using biomarker-defined hepatotoxicity. Of note, 
use of TPV and darunavir are still too limited to allow for robust statistical analyses in 
D:A:D. Furthermore, our analysis did not consider any impact of DAAs for treatment of 
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HCV, where there are known drug-drug interactions with PIs, as the use of DAAs in 
D:A:D is still extremely low. 
Limitations 
The limitations of this analysis should be acknowledged and include the lack of a 
systematic collection on information on alcohol consumption. However, the 
associations observed with use of ddI, d4T, TDF, APV, NVP and FTC are unlikely to be 
confounded by alcohol usage, as  the choice of ART including these ARVs is unlikely to 
be modified by the clinician’s knowledge of the individuals alcohol consumption. A 
high number of ARVs were included in the analysis, hence we cannot rule out that 
findings may be a result of multiple testing and the possibility of false positive error. 
Confounding by indication cannot be ruled out for a number of the included ARVs, in 
particular APV and NVP. Finally, non-ARV hepatotoxic treatment such as anti-TB 
treatment with isoniazid and rifampicin, or sulphonamides used to treat PCP may 
represent unmeasured confounding although adjustment for previous AIDS events did 
not change any of the observed ARV associations.  
Conclusion 
Whilst the ESLD/HCC incidence was relatively low in this large heterogeneous cohort, 
and predominantly seen in individuals with viral hepatitis co-infection the prognosis 
following a diagnosis was very poor. Cumulative use of ddI, d4T, TDF and APV was 
independently associated with increased rates of ESLD/HCC, while use of NVP and FTC 
was associated with lower rates. There was no evidence for reversibility of ESLD/HCC 
risk upon cessation of d-drugs, and intensified monitoring of liver function and 
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avoidance of hepatotoxic compounds should hence be considered amongst all with 
longer-term current or prior d-drug exposure. The unexpected and viral hepatitis 
independent, TDF association calls for further investigations, whilst use of d-drugs 
should be avoided, where there are alternatives available.   
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The Brussels St Pierre Cohort (Belgium):Coordination: S. De Wit*, N. Clumeck, M. 
Delforge, C. Necsoi. Participating physicians: N. Clumeck, S. De Wit*, AF Gennotte, M. 
Gerard, K. Kabeya, D. Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille, Y. Van 
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J. Sampson (Portland, Oregon); J. Baxter (Camden, New Jersey). 
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Copenhagen; C Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby 
Hospital, Aarhus. 
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, 
Nakkusosakond Siseklinik, Kohtla-Järve.  
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki.  
France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P Viard, Hôpital Necker-
Enfants Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital 
Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, Hôpital 
de l'Archet, Nice; F Dabis*, D Neau, Unité INSERM, Bordeaux.  
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule 
Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, 
Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S 
Staszewski, JW Goethe University Hospital, Frankfurt; M Bickel, Medizinische Poliklinik, 
Munich; G. Fätkenheuer, Universität Köln, Cologne.  
Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General Hospital; 
G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambatakou, Ippokration 
Genereal Hospital, Athens.  
Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest.  
Ireland: (F Mulcahy), St. James's Hospital, Dublin.  
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, 
Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem.  
Italy: (S Vella), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale 
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Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, 
Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E 
Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; 
G Antonucci, A Testa, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale Malattie 
Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San 
Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte, Istituto 
Di Clinica Malattie Infettive e Tropicale, Milan.  
Latvia: (B Rozentale), I Zeltina, Infectology Centre of Latvia, Riga.  
Lithuania: (S Chaplinskas), Lithuanian AIDS Centre, Vilnius.  
Luxembourg: (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.  
Netherlands: (P Reiss*), Academisch Medisch Centrum bij de Universiteit van 
Amsterdam, Amsterdam.  
Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.  
Poland: (B Knysz) J Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska, 
Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak, Medical 
University, Bialystok; A Boron-Kaczmarska, M Pynka, M Parczewski, Medical Univesity, 
Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H 
Trocha, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, 
Wojewodzki Szpital Specjalistyczny, Lodz.  
Portugal: (F Antunes), M Doroana, L Caldeira, Hospital Santa Maria, Lisbon; K 
Mansinho, Hospital de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
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Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; N 
Zakharova, St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre for 
AIDS, Novgorod.  
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.  
Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bratislava.  
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.  
Spain: (J González-Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; 
S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C 
Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; JM Gatell, JM Miró, 
Hospital Clinic i Provincial, Barcelona; P Domingo, M Gutierrez, G Mateo, MA Sambeat, 
Hospital Sant Pau, Barcelona.  
Sweden: (A Karlsson), Venhaelsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö 
University Hospital, Malmö.  
Switzerland: (B Ledergerber), R Weber*, University Hospital, Zürich; P Francioli, M 
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, 
Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; M 
Battegay, L Elzi, University Hospital Basel.  
Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev; V Frolov, G Kutsyna, 
Luhansk State Medical University; Luhansk; S Servitskiy, Odessa Region AIDS Center, 
Odessa; M Krasnov, Kharkov State Medical University, Kharkov.  
United Kingdom: (S Barton), St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, D Mercey, Royal Free and University College London Medical 
School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, Royal 
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Free and University College Medical School, London (Royal Free Campus); M Murphy, 
Medical College of Saint Bartholomew's Hospital, London; J Weber, G Scullard, Imperial 
College School of Medicine at St. Mary's, London; M Fisher, Royal Sussex County 
Hospital, Brighton; C Leen, Western General Hospital, Edinburgh. 
HivBivus (Sweden): 
Central coordination: L. Morfeldt*, G. Thulin, A. Sundström. 
Participating physicians (city): B. Åkerlund (Huddinge); K. Koppel, A. Karlsson 
(Stockholm); L. Flamholc, C. Håkangård (Malmö). 
The ICONA Foundation (Italy): 
Board of directors: M. Moroni (Chair), G. Angarano, A. Antinori, O. Armignacco, A. 
d’Arminio Monforte*, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R. Iardino, G. Ippolito, 
A. Lazzarin, C.F. Perno, F. von Schloesser, P. Viale  
Scientific secretary: A d’Arminio Monforte*, A. Antinori, A. Castagna, F. Ceccherini-
Silberstein, A. Cozzi-Lepri, E. Girardi, S. Lo Caputo, C. Mussini, M. Puoti 
ICONA Steering Committee: M. Andreoni, A. Ammassari, A. Antinori, A. d’Arminio 
Monforte, C. Balotta, P. Bonfanti, S. Bonora, M. Borderi, R. Capobianchi, A. Castagna, F. 
Ceccherini-Silberstein, A. Cingolani, P. Cinque, A. Cozzi-Lepri, A. De Luca, A. Di Biagio, E. 
Girardi, N. Gianotti, A. Gori, G. Guaraldi, G. Lapadula, M. Lichtner, S. Lo Caputo, G. 
Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, C. Mussini, M. Puoti, E. 
Quiros Roldan, S. Rusconi. 
Statistical and monitoring team: A.Cozzi-Lepri, P. Cicconi, I. Fanti, T. Formenti, L. Galli, 
P. Lorenzini. 
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Participating physicians and centers: A. Giacometti, A. Costantini (Ancona); G. 
Angarano, L. Monno, C. Santoro (Bari); F. Maggiolo, C. Suardi (Bergamo); P. Viale, E. 
Vanino, G. Verucchi (Bologna); F. Castelli, E. Quiros Roldan, C. Minardi (Brescia); T. 
Quirino, C. Abeli (Busto Arsizio); P.E. Manconi, P. Piano (Cagliari); J. Vecchiet, K. Falasca 
(Chieti); L. Sighinolfi, D. Segala (Ferrara); F. Mazzotta, S. Lo Caputo (Firenze); G. 
Cassola, G. Viscoli, A. Alessandrini, R. Piscopo, G. Mazzarello (Genova); C. Mastroianni, 
V. Belvisi (Latina); P. Bonfanti, I. Caramma (Lecco); A. P. Castelli (Macerata); M. Galli, A. 
Lazzarin, G. Rizzardini, M. Puoti, A. d’Arminio Monforte, A.L. Ridolfo, R. Piolini, A. 
Castagna, S. Salpietro, L. Carenzi, M.C. Moioli, P. Cicconi, G. Marchetti (Milano); C. 
Mussini, C. Puzzolante (Modena); A. Gori, G. Lapadula (Monza); N. Abrescia, A. 
Chirianni, M.G. Guida, M. ONOFRIO (Napoli); F. Baldelli, D. Francisci (Perugia); G. 
Parruti, T. Ursini (Pescara); G. Magnani, M.A. Ursitti (Reggio Emilia); R. Cauda, M. 
Andreoni, A. Antinori, V. Vullo, A. Cingolani, A. d’Avino, A. Ammassari, L. Gallo, E. 
Nicastri, R. Acinapura, M. Capozzi, R. Libertone, G. Tebano (Roma); A. Cattelan 
(Rovigo); M.S. Mura, G. Madeddu (Sassari); P. Caramello, G. Di Perri, G.C. Orofino, S. 
Bonora, M. Sciandra (Torino); G. Pellizzer, V. Manfrin (Vicenza). 
Nice HIV Cohort (France):  
Central coordination: C. Pradier*, E. Fontas, C. Caissotti.  
Participating physicians: P. Dellamonica, E. Bernard, E. Cua, F. De Salvador-Guillouet, J. 
Durant, S. Ferrando, V. Mondain-Miton, A. Naqvi, I. Perbost, B. Prouvost-Keller, S. 
Pillet, P. Pugliese, V. Rahelinirina, P.M. Roger. 
Clinical research assistant: K. Dollet 
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SHCS (Swiss HIV Cohort Study, Switzerland):                                                                                                      
Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, 
Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the 
Clinical and Laboratory Committee), Fux CA, Gorgievski M, Günthard H (President of 
the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, 
Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, 
Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, 
Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head of Data 
Center), Rudin C (Chairman of the Mother & Child Substudy), Schöni-Affolter F, Schmid 
P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R*, Yerly S. 
The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 
15 affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/31-
health-care-providers). 
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Table 1. Characteristics of persons included in analysis 
 at baseline and at the time of ESLD/HCC 
 All eligible 
participants at 
baseline 
At the time of an 
ESLD/HCC event 
Number of participants 45,544 (100.0) 319 (100.0) 
Gender Male 33,465 (73.5) 254 (79.6) 
 Female 12,079 (26.5) 65 (20.4) 
Age (years) Median (IQR) 40 (34-46) 47 (42-52) 
Mode of acquisition MSM 20,284 (44.5) 64 (20.1) 
 IDU 6,396 (14.0) 171 (53.6) 
 Heterosexual 15,316 (33.6) 67 (21.0) 
 Other/unknown 3,548 (7.8) 17 (5.3) 
Ethnicity Caucasian 22,609 (49.6) 180 (56.4) 
 Black African 4,263 (9.4) 12 (3.8) 
 Other 1,265 (2.8) 1 (0.3) 
 Unknown 17,407 (38.2) 126 (39.5) 
CD4 count (cells/mm3) Median (IQR) 434 (282-621) 266 (153-448) 
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HIV RNA (log10 
copies/mL) 
Median (IQR) 2.3 (1.7-4.3) 1.7 (1.7-2.6) 
HCV status* Negative 29,002 (63.7) 71 (22.3) 
 Positive  8,259 (18.1) 231 (72.4) 
 Unknown 8,283 (18.2) 17 (5.3) 
HBV status** Negative 30,690 (67.5) 174 (54.6) 
 Positive active 2,074 (4.6) 63 (19.8) 
 Positive inactive 6,021 (13.2) 64 (20.1) 
                          Unknown         6,759 (14.8) 18 (5.6) 
Smoking status Current smoker 17,443 (38.7) 180 (56.4) 
 Ex smoker 7,682 (17.0) 84 (26.3) 
 Never smoker 11,909 (26.4) 43 (13.5) 
 Not known 8,089 (17.9) 12 (3.8) 
Previous AIDS  10,846 (23.8) 155 (48.6) 
* HCV status (Negative: seronegative, or seropositive but HCV-RNA negative. Positive: seropositive and 
HCV-RNA positive or HCV-RNA unknown or not tested) 
** HBV status (positive: active infection [HB surface antigen, HB e antigen, or HBV DNA positive]; 
positive: inactive infection [HB surface antigen positive, anti-HB e antibody positive, or HBV DNA 
negative]) 
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Tabel 2. Incidence of ESLD/HCC (per 1000 PYFU) stratified by viral hepatitis status 
Factor  Number of 
events 
PYFU Rate  (95% CI) 
Overall  319 315,368 1.01 (0.90-1.12) 
HCV status* Negative   72 229,434 0.31 (0.24-0.39) 
 Positive 229 63,786 3.59 (3.13-4.06) 
 Unknown   18 22,148 0.81 (0.48-1.28) 
HBV status** Negative 175 242,901 0.72 (0.61-0.83) 
 Positive- 
active 
  59 12,907 4.57 (3.40-5.74) 
 Positive- 
inactive 
  65 42,016 1.55 (1.17-1.92) 
 Unknown   20 17,545 1.14 (0.64-1.64) 
* HCV status (Negative: seronegative, or seropositive but HCV-RNA negative. Positive: seropositive and 
HCV-RNA positive or HCV-RNA unknown or not tested) 
** HBV status (positive: active infection [HB surface antigen, HB e antigen, or HBV DNA positive]; 
positive: inactive infection [HB surface antigen positive, anti-HB e antibody positive, or HBV DNA 
negative]) 
46 
 
46 
 
                        Figure 1. Association between cumulative (per 5 year) ARV exposure and ESLD/HCC 
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Table 3. Associations between current, cumulative and past exposure to d-drugs (ddI and d4T) and rates of ESLD/HCC  
   Adjusted for: 
 Rate of ESLD/HCC 
(per 1000 PYFUa, 
95% CIa) 
No other factor Exposure to other NRTIs, 
PIs and NNRTIs 
Exposure to other NRTIs, 
PIs and NNRTIs and 
potential confoundersc 
 Relative rateb 
(95% CI) 
Relative rate  
(95% CI) 
Relative rate 
(95% CI) 
Never received d-drugs 0.50 (0.40, 0.61) 0.60 (0.37, 0.98) 0.65 (0.40, 1.05) 1.03 (0.60, 1.73) 
Currently on d-drugs 1.30 (0.87, 1.76) Ref. Ref. Ref. 
Stopped d-drugs and off for:     
>0, <2 years 1.89 (1.32, 2.45) 1.70 (1.07, 2.69) 1.72 (1.08, 2.72) 1.64 (1.03, 2.60) 
>2, <4 years 1.85 (1.30, 2.41) 1.60 (1.01, 2.52) 1.65 (1.04, 2.61) 1.59 (1.00, 2.52) 
>4, <6 years 1.93 (1.36, 2.50) 1.63 (1.04, 2.56) 1.72 (1.09, 2.73) 1.63 (1.03, 2.59) 
>6, <8 years 1.56 (1.00, 2.12) 1.34 (0.81, 2.20) 1.48 (0.89, 2.46) 1.48 (0.89, 2.47) 
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>8 years 1.40 (0.95, 1.85) 1.25 (0.78, 2.01) 1.44 (0.88, 2.36) 1.49 (0.90, 2.47) 
Cumulative exposure (/year) 
to d-drugs 
n/a 1.07 (1.03, 1.11) 1.07 (1.03, 1.12) 1.06 (1.01, 1.10) 
aPYFU: person-years of follow-up; CI: confidence interval; b adjusted for time since stopping d-drug and cumulative exposure to d-drug; cAge, gender, injection drug 
use as mode of HIV acquisition, previous AIDS diagnosis, viral hepatitis B/C co-infection, calendar period, time since stopping d-drug and cumulative exposure to d-
drugs 
 
